Cassava Sciences(SAVA) Prnewswire·2025-02-09 15:45Core Viewpoint - A securities class action lawsuit has been filed against Cassava Sciences, Inc. for allegedly making false and misleading statements regarding its drug simufilam and its effectiveness in treating Alzheimer's Disease during the specified Class Period from February 7, 2024, to November 24, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired Cassava securities during the Class Period [1]. - The lead plaintiff deadline for the lawsuit is February 10, 2025 [1]. - The complaint alleges that Cassava's drug simufilam was not capable of abating the progression of Alzheimer's Disease, which misrepresented the company's business and prospects [2]. Group 2: Legal Process - Investors may seek to be appointed as a lead plaintiff representative by the deadline or may choose to remain absent [3]. - The lead plaintiff will act on behalf of all class members and select counsel to represent the class [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].